Justin Yorke Biography and Net Worth

Director of Heatwurx

Mr. Yorke has over 25 years' experience as an institutional equity fund manager and senior financial analyst for investment funds and investment banks and was appointed a director of the Company in September 2017. For more than the past 10 year he has been a manager of the San Gabriel Fund, JMW Fund and the Richland Fund whose primary activity is investing public and private companies in the United States. Mr. Yorke served as non-executive Chairman of Jed Oil and a Director/CEO at JMG Exploration. Mr. Yorke was a Fund Manager and Senior Financial Analyst, based in Hong Kong, for Darier Henstch, S.A., a private Swiss bank, where he managed their $400 million Asian investment portfolio. Mr. Yorke was an Assistant Director and Senior Financial Analyst with Peregrine Asset Management, which was a unit of Peregrine Securities, a regional Asian investment bank. Mr. Yorke was a Vice President and Senior Financial Analyst with Unifund Global Ltd., a private Swiss Bank, as a manager of its $150 million Asian investment portfolio. Mr. Yorke has a B.A. from University of California, Los Angeles.

What is Justin W. Yorke's net worth?: The estimated net worth of Justin W. Yorke is at least $3.36 thousand as of January 27th, 2025. Mr. Yorke owns 12,400 shares of Heatwurx stock worth more than $3,363 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Yorke may own. Learn More about Justin W. Yorke's net worth.
How do I contact Justin W. Yorke?: The corporate mailing address for Mr. Yorke and other Heatwurx executives is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. Heatwurx can also be reached via phone at (443) 776-3133 and via email at [email protected]. Learn More on Justin W. Yorke's contact information.
Has Justin W. Yorke been buying or selling shares of Heatwurx?: Justin W. Yorke has not been actively trading shares of Heatwurx over the course of the past ninety days. Most recently, on Monday, January 27th, Justin W. Yorke bought 12,400 shares of Heatwurx stock. The stock was acquired at an average cost of $0.80 per share, with a total value of $9,920.00. Following the completion of the transaction, the director now directly owns 12,400 shares of the company's stock, valued at $9,920. Learn More on Justin W. Yorke's trading history.
Who are Heatwurx's active insiders?: Heatwurx's insider roster includes Robert Floyd (COO), Patrick Lin (Insider), James Stanker (CFO), Justin Yorke (Director), and David Young (CEO). Learn More on Heatwurx's active insiders.
Are insiders buying or selling shares of Heatwurx?: During the last year, Heatwurx insiders bought shares 3 times. They purchased a total of 224,100 shares worth more than $179,280.00. The most recent insider tranaction occured on January, 27th when CEO George K Ng bought 87,200 shares worth more than $69,760.00. Insiders at Heatwurx own 2.4% of the company. Learn More about insider trades at Heatwurx.
Information on this page was last updated on 1/27/2025.

Justin W. Yorke Insider Trading History at Heatwurx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/27/2025	Buy	12,400	$0.80	$9,920.00	12,400
1/30/2024	Buy	8,000	$2.69	$21,520.00	31,232
1/27/2022	Sell	92	$66.00	$6,072.00
12/6/2021	Sell	210	$94.20	$19,782.00
12/3/2021	Sell	275	$96.80	$26,620.00
4/13/2021	Sell	325	$197.20	$64,090.00	15,035
4/13/2021	Sell	325	$197.20	$64,090.00	15,035

Justin W. Yorke Buying and Selling Activity at Heatwurx

Heatwurx Company Overview

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Today's Range

Now: $0.27

$0.26

$0.29

50 Day Range

MA: $0.31

$0.19

$0.48

2 Week Range

Now: $0.27

$0.15

$1.50

Volume

1,515,478 shs

Average Volume

1,286,689 shs

Market Capitalization

$15.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09